Literature DB >> 9354459

Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

S R Denmeade1, W Lou, J Lövgren, J Malm, H Lilja, J T Isaacs.   

Abstract

Prostate-specific antigen (PSA) is a serine protease secreted by both normal prostate glandular cells and prostate cancer cells. The major proteolytic substrates for PSA are the gel-forming proteins in semen, semenogelin (Sg) I and II. On the basis of the PSA cleavage map for Sg I and II, a series of small peptides (i.e., < or = 7 amino acids) was synthesized and coupled at the COOH terminus to 7-amino-4-methyl coumarin. Using these fluorescently tagged substrates, K(m)s and k(cat)s were determined for PSA hydrolysis, and the substrates were also tested for activity against a panel of purified proteases. Previously, a variety of chymotrypsin substrates have been used to assay the enzymatic activity of PSA. The present studies have identified a peptide sequence with a high degree of specificity for PSA (ie., no detectable hydrolysis by chymotrypsin) and improved K(m)s and k(cat)s over previously used substrates. On the basis of these parameters, the best peptide substrate for PSA has the amino acid sequence HSSKLQ. Using PC-82 human prostate cancer xenografts and human prostate tissues, this PSA substrate was used to document that prostate cancer cells secrete enzymatically active PSA into the extracellular fluid but that once in the blood, PSA is not enzymatically active. On the basis of this information, it should be possible to use the HSSKLQ peptide as a carrier to target peptide-coupled prodrugs for selective activation within sites of PSA-secreting, metastatic prostate cancer cells and not within the blood or other nonprostatic normal tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354459      PMCID: PMC4124613     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Human prostate-specific antigen: structural and functional similarity with serine proteases.

Authors:  K W Watt; P J Lee; T M'Timkulu; W P Chan; R Loor
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

2.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

3.  Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity.

Authors:  J Lövgren; T Piironen; C Overmo; B Dowell; M Karp; K Pettersson; H Lilja; A Lundwall
Journal:  Biochem Biophys Res Commun       Date:  1995-08-24       Impact factor: 3.575

4.  Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82).

Authors:  W Hoehn; F H Schroeder; J F Reimann; A C Joebsis; P Hermanek
Journal:  Prostate       Date:  1980       Impact factor: 4.104

5.  Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex.

Authors:  K Pettersson; T Piironen; M Seppälä; L Liukkonen; A Christensson; M T Matikainen; M Suonpää; T Lövgren; H Lilja
Journal:  Clin Chem       Date:  1995-10       Impact factor: 8.327

6.  Cathepsin B: association with plasma membrane in metastatic tumors.

Authors:  B F Sloane; J Rozhin; K Johnson; H Taylor; J D Crissman; K V Honn
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

7.  Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.

Authors:  M M Webber; A Waghray; D Bello
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

8.  The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.

Authors:  Y Furuya; P Lundmo; A D Short; D L Gill; J T Isaacs
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

9.  The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein.

Authors:  K Akiyama; T Nakamura; S Iwanaga; M Hara
Journal:  FEBS Lett       Date:  1987-12-10       Impact factor: 4.124

10.  Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells.

Authors:  E Krepela; J Bártek; D Skalková; J Vicar; D Rasnick; J Taylor-Papadimitriou; R C Hallowes
Journal:  J Cell Sci       Date:  1987-02       Impact factor: 5.285

View more
  48 in total

1.  Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.

Authors:  Meredith R Clark; Hyder A Aliyar; Chang-won Lee; Julie I Jay; Kavita M Gupta; Karen M Watson; Russell J Stewart; Robert W Buckheit; Patrick F Kiser
Journal:  Int J Pharm       Date:  2011-04-12       Impact factor: 5.875

Review 2.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

3.  Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

4.  PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Authors:  Maya B Kostova; William Nathaniel Brennen; David Lopez; Lizamma Anthony; Hao Wang; Elizabeth Platz; Samuel R Denmeade
Journal:  Prostate       Date:  2018-04-16       Impact factor: 4.104

5.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

6.  Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.

Authors:  Kailash C Chadha; Bindukumar B Nair; Srikant Chakravarthi; Rita Zhou; Alejandro Godoy; James L Mohler; Ravikumar Aalinkeel; Stanley A Schwartz; Gary J Smith
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

7.  Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Samuel R Denmeade; Blair Egerdie; Gary Steinhoff; Rosemina Merchant; Ralph Abi-Habib; Peter Pommerville
Journal:  Eur Urol       Date:  2010-11-24       Impact factor: 20.096

8.  Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.

Authors:  Simon A Williams; Yi Xu; Angelo M De Marzo; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

9.  Molecular insights into substrate specificity of prostate specific antigen through structural modeling.

Authors:  Pratap Singh; Aaron M LeBeau; Hans Lilja; Samuel R Denmeade; John T Isaacs
Journal:  Proteins       Date:  2009-12

10.  Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.

Authors:  Raghunath Shobana; Siba K Samal; Subbiah Elankumaran
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.